Accuray Signs Three-Year Contract with Amerinet
Gains access to over 3,000 member hospitals for the CyberKnife® M6TM and TomoTherapy® HTM Series.
SUNNYVALE, Calif., May 6, 2014 - Accuray Incorporated (Nasdaq: ARAY) announced today that it has signed a new three-year contract with Amerinet on the CyberKnife® M6TM and TomoTherapy® HTM product portfolio.
"We are pleased to be an Amerinet radiation oncology solutions provider and see this as a great opportunity to increase the visibility of our products and services to their expansive network of partners," said Kelly Londy, executive vice president and chief commercial officer of Accuray.
Under the new agreement, Accuray Incorporated's precise, leading-edge technologies, delivering the full range of radiation therapy and radiosurgery treatments, are immediately available to the hospitals that Amerinet serves.
"This agreement with Amerinet for radiation oncology, linear accelerators, significantly enhances our GPO strategic accounts contract portfolio," said Joshua H. Levine, president and chief executive officer of Accuray. "Accuray can now provide products and services under contract, where cost savings and innovative technologies allow for a better patient experience as well as workflow improvements for the treatment of cancer with external beam radiation. Accuray also has the opportunity to participate in Amerinet TargetBuy promotions that provide Amerinet membership significant savings on product cost, enhancements and service support beyond the standard contract."
As a leading national healthcare solutions organization, Amerinet collaborates with acute and non-acute care providers to create and deliver unique solutions through performance improvement resources, guidance and ongoing support. With better product standardization and utilization, new financial tools beyond contracting and alliances that help lower costs, raise revenue and champion quality, Amerinet enriches healthcare delivery for its members and the communities they serve. To learn more about how Amerinet can help you successfully navigate the future of healthcare reform, visit www.amerinet-gpo.com.
About the CyberKnife and TomoTherapy Systems
The CyberKnife M6 Series and the TomoTherapy H Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to market access, future sales orders and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from under the heading "Risk Factors" in Accuray's report on Form 10-K which was filed on August 29, 2013, and its reports on Form 10-Q, which were filed on November 8, 2013 and February 7, 2014.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.